# US 2004/0082802 A1 · 26,27-Homologated-20-EPI-2-alkyl-19-nor-vitamin D compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082802 A1
- Document ID: US20040082802A1
- Status: Published application
- Kind: A1
- Application number: 10/683,330
- Filed: 2003-10-10
- Published: 2004-04-29
- Earliest claimed: 1997-03-17
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: Hector F. DeLuca; Rafal R. Sicinski
- Web page: https://patentgrep.com/patent/US20040082802A1

## CPC

- C07C 401/00: Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- A61P 17/06: Antipsoriatics
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

This invention provides a novel class of vitamin D related compounds, namely, the 2-alkyl-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: 1 where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 is selected from the group consisting of alkyl, hydroxyalkyl and fluoroalkyl, and where the group R represents any of the typical side chains known for vitamin D type compounds. These 2-substituted compounds, especially the 2α-methyl and the 2α-methyl-20S derivatives, are characterized by relatively high intestinal calcium transport activity and relatively high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.

## Claims

### Claim 1

A compound having the formula:
18
where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 is selected from alkyl, hydroxyalkyl and fluoroalkyl, and where the group R is represented by the structure:
19
where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —OY, —CH2OY, —C≡CY, —CH═CHY, and —CH2CH2CH═CR3R4, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —COR5 and a radical of the structure:
20
where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═CR2R3, or the group —(CH2)p—, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —(CH2)q—, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, C1-5 alkyl or —OR7 where R7 represents C1-5 alkyl, and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —CH(CH3)—, —CH(R3)—, or —CH(R2)— at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.

### Claim 2 (depends on 1)

The compound of claim 1 where R is a side chain of the formula
21

### Claim 3 (depends on 1)

The compound of claim 1 where R is a side chain of the formula
22

### Claim 4

19-nor-26,27-dihomo-20(S)-2α-methyl-1α,25-dihydroxyvitamin D3.

### Claim 5

19-nor-26,27-dihomo-20(S)-2β-methyl-1α,25-dihydroxyvitamin D3.

### Claim 6

19-nor-26,27-dimethylene-20(S)-2α-methyl-1α,25-dihydroxyvitamin D3.

### Claim 7

19-nor-26,27-dimethylene-20(S)-2β-methyl-1α,25-dihydroxyvitamin D3.

### Claim 8 (depends on 1)

A pharmaceutical composition containing at least one compound as claimed in claim 1 together with a pharmaceutically acceptable excipient.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8 containing 19-nor-26,27-dihomo-20(S)-2α-methyl-1α,25-dihydroxyvitamin D3 in an amount from about 0.1 μg to about 50 μg.

### Claim 10 (depends on 8)

The pharmaceutical composition of claim 8 containing 19-nor-26,27-dihomo-20(S)-2β-methyl-1α,25-dihydroxyvitamin D3 in an amount from about 0.1 μg to about 50 μg.

### Claim 11 (depends on 8)

The pharmaceutical composition of claim 8 containing 19-nor-26,27-dimethylene-20(S)-2α-methyl-1α,25-dihydroxyvitamin D3 in an amount from about 0.1 μg to about 50 μg.

### Claim 12 (depends on 8)

The pharmaceutical composition of claim 8 containing 19-nor-26,27-dimethylene-20(S)-2β-methyl-1α,25-dihydroxyvitamin D3 in an amount from about 0.1 μg to about 50 μg.

### Claim 13

A method of treating metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of a compound having the formula:
23
where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 is selected from alkyl, hydroxyalkyl and fluoroalkyl, and where the group R is represented by the structure:
24
where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —OY, —CH2OY, —C≡CY, —CH═CHY, and —CH2CH2CH═CR3R4, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —COR5 and a radical of the structure:
25
where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═CR2R3, or the group —(CH2)p—, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —(CH2)q—, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, C1-5 alkyl or —OR7 where R7 represents C1-5 alkyl, and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —CH(CH3)—, —CH(R3)—, or —CH(R2)— at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.

### Claim 14 (depends on 13)

The method of claim 13 where the disease is senile osteoporosis.

### Claim 15 (depends on 13)

The method of claim 13 where the disease is postmenopausal osteoporosis.

### Claim 16 (depends on 13)

The method of claim 13 where the disease is steroid-induced osteoporosis.

### Claim 17 (depends on 13)

The method of claim 13 where the disease is low bone turnover osteoporosis.

### Claim 18 (depends on 13)

The method of claim 13 where the disease is osteomalacia.

### Claim 19 (depends on 13)

The method of claim 13 where the disease is renal osteodystrophy.

### Claim 20 (depends on 13)

The method of claim 13 wherein the compound is administered orally.

### Claim 21 (depends on 13)

The method of claim 13 wherein the compound is administered parenterally.

### Claim 22 (depends on 13)

The method of claim 13 wherein the compound is administered transdermally.

### Claim 23 (depends on 13)

The method of claim 13 wherein the compound is administered in a dosage of from 0.1 μg to 50 μg per day.

### Claim 24 (depends on 13)

The method of claim 13 wherein the compound is 19-nor-26,27-dihomo-20(S)-2α-methyl-1α,25-dihydroxyvitamin D3.

### Claim 25 (depends on 13)

The method of claim 13 wherein the compound is 19-nor-26,27-dihomo-20(S)-2β-methyl-1α,25-dihydroxyvitamin D3.

### Claim 26 (depends on 13)

The method of claim 13 wherein the compound is 19-nor-26,27-dimethylene-20(S)-2α-methyl-1α,25-dihydroxyvitamin D3.

### Claim 27 (depends on 13)

The method of claim 13 wherein the compound is 19-nor-26,27-dimethylene-20(S)-2β-methyl-1α,25-dihydroxyvitamin D3.

### Claim 28

A method of treating psoriasis comprising administering to a patient with said disease an effective amount of a compound having the formula:
26
where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 is selected from alkyl, hydroxyalkyl and fluoroalkyl, and where the group R is represented by the structure:
27
where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —OY, —CH2OY, —C≡CY, —CH═CHY, and —CH2CH2CH═CR3R4, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —COR5 and a radical of the structure:
28
where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3; and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═CR2R3, or the group —(CH2)p—, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —(CH2)q—, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, C1-5 alkyl or —OR7 where R7 represents C1=5 alkyl, and wherein any of the CH-groups at positions 20,22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —CH(CH3)—, —CH(R3)—, or —CH(R2)— at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.

### Claim 29 (depends on 28)

The method of claim 28 wherein the compound is 19-nor-26,27-dihomo-20(S)-2α-methyl-1α,25-dihydroxyvitamin D3.

### Claim 30 (depends on 28)

The method of claim 28 wherein the compound is 19-nor-26,27-dihomo-20(S)-2β-methyl-1α,25-dihydroxyvitamin D3.

### Claim 31 (depends on 28)

The method of claim 28 wherein the compound is 19-nor-26,27-dimethylene-20(S)-2α-methyl-1α,25-dihydroxyvitamin D3.

### Claim 32 (depends on 28)

The method of claim 28 wherein the compound is 19-nor-26,27-dimethylene-20(S)-2β-methyl-1α,25-dihydroxyvitamin D3.

### Claim 33 (depends on 28)

The method of claim 28 wherein said effective amount comprises about 0.01 μg/day to about 100 μg/day of said compound.

### Claim 34

A method of treating a cancerous disease comprising administering to a patient with said disease an effective amount of a compound having the formula:
29
where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 is selected from alkyl, hydroxyalkyl and fluoroalkyl, and where the group R is represented by the structure:
30
where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —OY, —CH2OY, —C≡CY, —CH═CHY, and —CH2CH2CH═CR3R4, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —COR5 and a radical of the structure:
31
where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═CR2R3, or the group —(CH2)p—, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —(CH2)q—, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, C1-5 alkyl or —OR7 where R7 represents C1-5 alkyl, and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —CH(CH3)—, —CH(R3)—, or —CH(R2)— at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.

### Claim 35 (depends on 34)

The method of claim 34 where the disease is leukemia.

### Claim 36 (depends on 34)

The method of claim 34 where the disease is colon cancer.

### Claim 37 (depends on 34)

The method of claim 34 where the disease is breast cancer.

### Claim 38 (depends on 34)

The method of claim 34 where the disease is prostate cancer.

### Claim 39 (depends on 34)

The method of claim 34 wherein the compound is administered orally.

### Claim 40 (depends on 34)

The method of claim 34 wherein the compound is administered parenterally.

### Claim 41 (depends on 34)

The method of claim 34 wherein the compound is administered transdermally.

### Claim 42 (depends on 34)

The method of claim 34 wherein the compound is administered in a dosage of from 0.1 μg to 50 μg per day.

### Claim 43 (depends on 34)

The method of claim 34 wherein the compound is 19-nor-26,27-dihomo-20(S)-2α-methyl-1α,25-dihydroxyvitamin D3.

### Claim 44 (depends on 34)

The method of claim 34 wherein the compound is 19-nor-26,27-dihomo-20(S)-2β-methyl-1α,25-dihydroxyvitamin D3.

### Claim 45 (depends on 34)

The method of claim 34 wherein the compound is 19-nor-26,27-dimethylene-20(S)-2α-methyl-1α,25-dihydroxyvitamin D3.

### Claim 46 (depends on 34)

The method of claim 34 wherein the compound is 19-nor-26,27-dimethylene-20(S)-2β-methyl-1α,25-dihydroxyvitamin D3.
